On this page

polymyxin b sulfate and trimethoprim sulfate

Prescription ANDA TE AT Official labelling
Informational index, not medical advice. Content is reproduced from public FDA and NLM data. Always confirm against the manufacturer's current prescribing information. Report adverse events to FDA MedWatch.

Overview

Brand name
polymyxin b sulfate and trimethoprim sulfate
Generic name
polymyxin b sulfate and trimethoprim sulfate
Dosage form
Solution/ Drops
Route
Ophthalmic
Marketing category
ANDA · ANDA
Labeler
REMEDYREPACK INC.
Product type
Human Prescription Drug
DEA schedule
Not scheduled
Active ingredients
2
NDC product codes
2
Packages
2
Data completeness
76% of corroborating sources present

Active ingredients

Source: NDC Directory
Active ingredients and strengths as listed in the NDC Directory.
Ingredient Strength RxCUI Monograph
Polymyxin B Sulfate 10000 [iU]/mL 204602 View
Trimethoprim 1 mg/mL 313137 View

Forms, strengths and routes

Source: NDC Directory
Dosage form
Solution/ Drops
Route of administration
Ophthalmic
Presentations
4

Pharmacologic classes are listed in the class section below.

Pharmacologic class

Source: NDC Directory
Established pharmacologic classes (EPC), mechanisms of action (MoA), chemical structures (CS) and physiologic effects (PE).
Class Type Browse
Cytochrome P450 2C8 Inhibitors [MoA] MoA All 56 members
Dihydrofolate Reductase Inhibitor Antibacterial [EPC] EPC 8 members — no class page
Dihydrofolate Reductase Inhibitors [MoA] MoA All 25 members
Organic Cation Transporter 2 Inhibitors [MoA] MoA All 32 members
Polymyxin-class Antibacterial [EPC] EPC All 55 members
Polymyxins [CS] CS All 55 members

Regulatory status

Source: Drugs@FDANDC Directory
Application number
211572
Application type
ANDA · Abbreviated New Drug Application
Approval date
August 5, 2024
Sponsor
SOMERSET THERAPS LLC
Products on application
1
Submissions recorded
1
Products approved under application 211572.
Product Trade name Form Strength Ingredient Status TE Flags
211572-001 TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE SOLUTION/DROPS POLYMYXIN B SULFATE; TRIMETHOPRIM SULFATE Prescription AT

Therapeutic equivalence

Source: Orange Book
TE code
AT
Reference Listed Drug
No
Reference Standard
No

What this rating means: Therapeutically equivalent — bioequivalence demonstrated (topical dermatological products)

Codes beginning with “A” indicate products the FDA considers therapeutically equivalent. Codes beginning with “B” indicate bioequivalence has not been established. See methodology.

Approval history

Source: Drugs@FDA
Most recent submissions on application 211572.
Type No. Action Status Date Review
Original application 1 Approved August 5, 2024 Standard

Prescribing information

Source: openFDA Drug Labeling

Reproduced verbatim from the Structured Product Labeling submitted to the FDA (effective 20240806). This is the manufacturer's labelling text, not a summary and not advice.

HUMAN PRESCRIPTION DRUG · 20240806

Indications and Usage

openFDA Drug Labeling

INDICATIONS AND USAGE Polymyxin B Sulfate and Trimethoprim Ophthalmic Solution, USP is indicated in the treatment of surface ocular bacterial infections, including acute bacterial conjunctivitis, and blepharoconjunctivitis, caused by susceptible strains of the following microorganisms: Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pneumoniae, Streptococcus viridans, Haemophilus influenzae and Pseudomonas aeruginosa. * * Efficacy for this organism in this organ system was studied in fewer than 10 infections.

Dosage and Administration

openFDA Drug Labeling

DOSAGE AND ADMINISTRATION In mild to moderate infections, instill one drop in the affected eye(s) every three hours (maximum of 6 doses per day) for a period of 7 to 10 days.

Contraindications

openFDA Drug Labeling

CONTRAINDICATIONS Polymyxin B Sulfate and Trimethoprim Ophthalmic Solution is contraindicated in patients with known hypersensitivity to any of its components.

WARNINGS NOT FOR INJECTION INTO THE EYE. If a sensitivity reaction to polymyxin B sulfate and trimethoprim ophthalmic solution occurs, discontinue use. Polymyxin B Sulfate and Trimethoprim Ophthalmic Solution is not indicated for the prophylaxis or treatment of ophthalmia neonatorum.

Adverse Reactions

openFDA Drug Labeling

ADVERSE REACTIONS The most frequent adverse reaction to polymyxin B sulfate and trimethoprim ophthalmic solution is local irritation consisting of increased redness, burning, stinging, and/or itching. This may occur on instillation, within 48 hours, or at any time with extended use. There are also multiple reports of hypersensitivity reactions consisting of lid edema, itching, increased redness, tearing, and/or circumocular rash. Photosensitivity has been reported in patients taking oral trimethoprim. To report SUSPECTED ADVERSE REACTIONS, contact Somerset Therapeutics, LLC at 1-800-417-9175 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch

Description

openFDA Drug Labeling

DESCRIPTION Polymyxin B Sulfate and Trimethoprim Ophthalmic Solution, USP is a sterile antimicrobial solution for topical ophthalmic use. It has pH of 4.0 to 6.2 and osmolality of 270 to 310 mOsm/kg. Chemical Names: Trimethoprim, 5-(3,4,5-Trimethoxybenzyl)pyrimidine-2,4-,diamine, is a white, odorless, crystalline powder with a molecular weight of 290.3 and the following structural formula: Structure Polymyxin B sulfate is the sulfate salt of polymyxin B 1 and B 2 which are produced by the growth of Bacillus polymyxa (Prazmowski) Migula (Fam. Bacillaceae). It has a potency of not less than 6,000 polymyxin B units per mg, calculated on an anhydrous basis. The structural formulae are: Structure Contains: Actives: polymyxin B sulfate 10,000 units/mL; trimethoprim sulfate equivalent to trimethoprim 1 mg/mL. Preservative: benzalkonium chloride 0.04 mg/mL. Inactives: water for injection; sodium chloride; and sulfuric acid. May also contain sodium hydroxide to adjust the pH. Molecular Structure Molecular Structure

How Supplied / Storage and Handling

openFDA Drug Labeling

HOW SUPPLIED Polymyxin B Sulfate and Trimethoprim Ophthalmic Solution, USP is supplied sterile in natural low density polyethylene (LDPE) ophthalmic bottles and natural low density polyethylene (LDPE) nozzle with white high density polyethylene (HDPE) caps as follows: 10 mL in 10 mL bottle - NDC 70069- 311 -01 Note: Store at 15° to 25°C (59° to 77°F) and protect from light. Rx only For Product Inquiry call +1-800-417-9175 Revised: May, 2024 Manufactured for: Somerset Therapeutics, LLC. Somerset, NJ 08873 Made in India Code No.: KR/DRUGS/KTK/28/289/97 ST-PST11/P/01 1200824

Adverse event reports

Source: openFDA FAERS
94,992
FAERS reports mentioning this drug
as of 2026-09-25T03:42:24+00:00
A report count is not a risk measure. FAERS accepts voluntary and mandatory reports without establishing causation, and reporting is influenced by how widely a drug is used, how long it has been marketed, and media attention. FDA states that reports “do not prove that the drug caused the event”. Compare rates, not totals.

Attributed to this product's most-reported active ingredient: TRIMETHOPRIM. Combination products with more than six active ingredients are not attributed, because a report count summed across a long ingredient list measures the list, not the medicine.

Packaging and NDCs

Source: NDC Directory
Every National Drug Code package associated with this medication. The NDC is the identifier used for dispensing, billing and pharmacovigilance in the United States.
Package NDC Product NDC Labeler Description Marketing start
70518-4381-0 70518-4381 REMEDYREPACK INC. 1 BOTTLE in 1 CARTON (70518-4381-0) / 10 mL in 1 BOTTLE July 1, 2025
70069-311-01 70069-311 Somerset Therapeutics, LLC 1 BOTTLE in 1 CARTON (70069-311-01) / 10 mL in 1 BOTTLE August 6, 2024
70518-4381 70518-4381 REMEDYREPACK INC. — July 1, 2025
70069-311 70069-311 Somerset Therapeutics, LLC — August 6, 2024

Sources for this page

Every dataset that contributed a fact to this page.
Dataset Agency Used for
NDC Directory FDA Identity, ingredients, strengths, forms, routes, labelers, packages
Drugs@FDA FDA Application, sponsor, submissions, review documents, marketing status
Orange Book FDA Therapeutic equivalence codes, reference drug flags, patents, exclusivity
Drug Labeling FDA / NLM Prescribing information reproduced above
FAERS FDA Adverse event report counts

Generated September 25, 2026 · 11 sections on this page.